摘要 |
<p>The present invention relates to aberrant cell signaling by the HIV type I envelope glycoprotein. In particular, the present invention provides compositions and methods for identification of inhibitors of melanocortin receptor pathway stimulation by HIV-I gp120 and its degradation products. The inhibitors so identified are contemplated to be suitable for treating HIV-related cachexia, T cell hyperactivation and central nervous system disease.</p> |